In this article, we will look at the 10 Small–Cap Stocks Insiders Are Buying Recently.
Insider buying tends to get attention for the simple reason that executives and directors usually know their own businesses better than outside investors do. That does not make every purchase a guaranteed win, but it can matter when insiders are buying after a stretch of weak sentiment or market overreaction. That signal can be even more interesting in small caps, where information gaps tend to be wider, and price swings can be sharper. Insider buying often offers a clue that management may see a disconnect between the current share price and the company’s underlying prospects.
That rationale shows up in how professional investors describe their own process. J.P. Morgan Asset Management says its Undiscovered Managers Behavioral Value Fund seeks to “capitalize on behavioral biases” and looks for “companies with significant insider buying or stock repurchases,” along with “evidence of overreaction that has caused devaluation” and “attractive fundamentals.” Meanwhile, Franklin Templeton, in its Value Balanced Portfolios factsheet, says it emphasizes companies with “healthy balance sheets” trading at “prices that do not accurately reflect cash flows, tangible assets or management skills.” It also says managers may “Re-examine a current holding” when “there is unusual insider buying/selling.” Taken together, these suggest insider transactions are treated as one of the signals professionals watch when they think the market may be mispricing a stock.
With that in mind, we will look at the 10 Small-Cap Stocks Insiders Are Buying Recently.
Our Methodology
We used the Finviz stock screener to identify small-cap companies with a significant increase in insider ownership over the last six months. We then limited our final selection to stocks that have recently reported noteworthy developments likely to influence investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. ACV Auctions Inc. (NYSE:ACVA)
On March 19, 2026, ACV Auctions Inc. (NYSE:ACVA) announced the launch of ACV MAX Recommendations, an AI-powered feature within its ACV MAX suite designed to “deliver profit-focused guidance” on vehicle pricing. The company said the tool provides recommendations based on real-time data, dealership history, and individual VINs, with Ryan Walker noting it removes “guesswork” and reduces decision bottlenecks while maintaining dealer control.
Last month, Barrington analyst Gary Prestopino upgraded ACV Auctions Inc. to Outperform from Market Perform with a $7-$9 price target range, describing the recent share selloff as “unwarranted” and expecting adjusted EBITDA growth to recover in 2026. Gary Prestopino added that there were no major concerns in the Q4 report and said expectations had been too aggressive.
Meanwhile, Citi analyst Ronald Josey downgraded ACV Auctions Inc. to Neutral from Buy with a price target of $7, down from $13, citing slower-than-expected share gains and a more challenging macro environment, while noting that benefits from new initiatives may not materialize until the second half of 2026 and into 2027.
ACV Auctions Inc. operates a wholesale auction marketplace for business-to-business used vehicle sales between dealerships.
9. Biohaven Ltd. (NYSE:BHVN)
On March 19, 2026, Biohaven Ltd. (NYSE:BHVN) announced the completion of enrollment in a Phase 2 proof-of-concept study of taldefgrobep alfa, a myostatin-activin pathway inhibitor aimed at achieving weight loss in people with obesity. The company expects topline data in the second half of 2026.
On March 11, 2026, TD Cowen analyst Ken Cacciatore raised the price target on Biohaven Ltd. to $30 from $15 and maintained a Buy rating. Ken Cacciatore updated the model following validation of the Kv7 mechanism of action in focal epilepsy based on azetukalner data and said this supports expectations ahead of topline opakalim data expected mid-year, while noting potential to highlight a differentiated CNS adverse event profile.
Earlier in March, Biohaven Ltd. reported Q4 adjusted EPS of (90c), compared to the (96c) consensus estimate. CEO Vlad Coric said the company made “significant progress” advancing its pipeline, highlighting its degrader platform as a “central pillar” of strategy and pointing to early evidence demonstrating the ability to target disease mechanisms while preserving immune function, supporting confidence in the platform’s potential.
Biohaven Ltd. develops therapies across immunology, neuroscience, and oncology.
8. Phreesia, Inc. (NYSE:PHR)
On March 24, 2026, Mizuho analyst Steven Valiquette lowered the price target on Phreesia, Inc. (NYSE:PHR) to $19 from $22 previously and maintained an Outperform rating ahead of the company’s fiscal Q4 report on March 30. Steven Valiquette said the firm is taking a more conservative approach to estimates following peer earnings reports.
On March 16, 2026, Phreesia, Inc. announced it refinanced its existing bridge loan by entering into a new credit agreement for a senior secured revolving credit facility of up to $275M, with Capital One serving as agent. The company borrowed about $92.2M at closing to repay all outstanding obligations under the bridge loan, which was terminated without penalty, and said remaining capacity may be used for working capital, capital expenditures, acquisitions, and other general corporate purposes.
Last month, JPMorgan analyst Alexei Gogolev lowered the price target on Phreesia, Inc. to $24 from $29 previously and maintained an Overweight rating.
Phreesia, Inc. provides a SaaS-based software and payment platform for healthcare providers in North America.
7. PAR Technology Corporation (NYSE:PAR)
On March 16, 2026, Benchmark lowered the price target on PAR Technology Corporation (NYSE:PAR) to $33 from $42 previously and maintained a Buy rating. Benchmark said the company’s announcement of a new, dilutive tranche of convertible debt led to a sharp negative market reaction, reflecting both the increase in fully diluted share count and investor confusion around the timing of the transaction.
On March 12, 2026, PAR Technology Corporation announced an offering of $225M in convertible senior notes due 2031.
Earlier in the month, Voss Capital, which beneficially owns about 13.2% of PAR Technology Corporation, issued an open letter urging the board to explore strategic alternatives. Voss Capital said the company’s “data moat” and positioning in enterprise restaurant and retail markets remain strong, but pointed to a “disconnect” between intrinsic value and public market valuation. The firm added that current market conditions are limiting PAR’s ability to pursue accretive M&A and argued that a strategic review could help “maximize shareholder value.”
PAR Technology Corporation provides cloud-based software and hardware solutions for the restaurant and retail industries.
6. Kosmos Energy Ltd. (NYSE:KOS)
On March 24, 2026, Johnson Rice analyst Charles Meade upgraded Kosmos Energy Ltd. (NYSE:KOS) to Buy from Accumulate with a $4.25 price target.
On March 22, 2026, Bernstein analyst Bob Brackett raised the price target on Kosmos Energy Ltd. to $1.10 from 80c and maintained a Market Perform rating. Bob Brackett updated models to reflect current crude prices and crack spreads, “while acknowledging a wide range of future outcomes,” adding that prolonged conflicts can last for years and citing “uncertainty and right tail risk” as a reason to recommend increased energy exposure.
Earlier in March, Kosmos Energy Ltd. announced a registered underwritten public offering of $175M in common stock, with proceeds intended to repay borrowings under its commercial debt facility and other outstanding debt. The deal size was later increased to $185.3M from $175M, with a pricing range of $1.90-$2.20. Barclays and Stifel acted as joint book-running managers for the offering.
Kosmos Energy Ltd. explores, develops, and produces oil and natural gas in deepwater regions.
5. Strive Asset Management, LLC (NASDAQ:ASST)
On March 23, 2026, Maxim lowered the price target on Strive Asset Management, LLC (NASDAQ:ASST) to $20 from $30 and maintained a Buy rating. Maxim said the stock remains a Bitcoin accumulation story with a strengthened balance sheet and differentiated access to capital, but reduced its target to reflect a lower assumed Bitcoin value of $100,000 versus $150,000 previously.
On March 19, 2026, Strive Asset Management, LLC reported adjusted EPS since listing of ($4.73) and revenue of $1.5M, while accumulating 13,628 bitcoin as of March 17, 2026. CEO Matthew Cole said the company is focused on digital credit as a “multi-trillion dollar opportunity,” highlighting its SATA product as a “liquid and scalable solution” aimed at delivering yield with limited volatility, while maintaining a strong balance sheet.
Earlier in March, B. Riley analyst Fedor Shabalin initiated coverage with a Buy rating and a $12 price target, describing the company’s model as “compelling” with a combination of bitcoin treasury and asset management, and pointing to its capital structure and valuation discount.
Strive Asset Management, LLC operates as an investment manager providing portfolio management services.
4. Grocery Outlet Holding Corp. (NASDAQ:GO)
On March 25, 2026, Grocery Outlet Holding Corp. (NASDAQ:GO) disclosed in a regulatory filing that CEO Jason Potter purchased 112.8K shares of common stock on March 23 in a transaction valued at $717.2K.
On March 9, 2026, BofA lowered its price target on Grocery Outlet Holding Corp. to $10.50 from $13 and maintained a Neutral rating, citing ongoing supply chain pressure and affordability challenges for core consumers, along with uncertain timing for recovery in comparable sales and basket size. DA Davidson also lowered its price target to $7 from $11 and kept a Neutral rating following a Q4 earnings miss and below-consensus guidance, noting that business trends weakened mid-year and continued to deteriorate into year-end and early 2026, while pointing to store closures and other initiatives aimed at stabilizing performance.
Earlier in March, Grocery Outlet Holding Corp. reported Q4 adjusted EPS of 19c, below the 21c consensus estimate, with revenue of $1.22B compared to $1.23B consensus, while comparable store sales declined 0.8%. CEO Jason Potter said the company has “more work to do,” citing intensified consumer pressure and increased promotional activity, and added that efforts are underway to improve value perception, refresh stores, and close underperforming locations to strengthen results.
Grocery Outlet Holding Corp. operates a network of retail stores offering consumables and fresh products in the United States.
3. Larimar Therapeutics, Inc. (NASDAQ:LRMR)
On March 20, 2026, Wedbush raised the price target on Larimar Therapeutics, Inc. (NASDAQ:LRMR) to $13 from $12 previously and maintained an Outperform rating. Wedbush said the Q4 update was in line with expectations as the company prepares for its nomlabofusp regulatory submission in June 2026, noting management reiterated a cash runway into Q2 2027 following recent financing, while near-term focus is on updated open-label data expected in Q2.
On March 19, 2026, Larimar Therapeutics, Inc. reported Q4 EPS of (73c), compared to the (55c) consensus estimate. As of December 31, 2025, the company had $136.9M in cash, cash equivalents, and marketable securities, along with $107.6M in net proceeds from a February 2026 public offering, supporting a projected cash runway into Q2 2027. Chief Executive Officer Carole Ben-Maimon said the company is advancing nomlabofusp toward registration, highlighting “Breakthrough Therapy Designation” and ongoing FDA engagement, while noting plans to submit a Biologics License Application in June 2026 and report topline data from an open-label study in Q2.
Larimar Therapeutics, Inc. develops treatments for rare diseases using its cell-penetrating peptide technology platform.
2. Thryv Holdings, Inc. (NASDAQ:THRY)
On March 24, 2026, Thryv Holdings, Inc. (NASDAQ:THRY) announced the launch of Thryv AI Lead Flow, an end-to-end solution that integrates online visibility, lead management, and automated sales follow-ups into a single platform designed to require no manual effort once implemented.
Last month, B. Riley analyst Zach Cummins lowered the price target on Thryv Holdings, Inc. to $5 from $15 and maintained a Buy rating, citing FY26 guidance that disappointed following a strategic shift toward an AI-native unified SaaS platform. Zach Cummins noted the change led to a 46% decline in the share price and said management expects near-term churn from smaller customers in the first half of 2026, with growth from higher-value clients supporting a return to growth and free cash flow expansion in the second half.
Thryv Holdings, Inc. reported revenue of $191.62M versus the $191.26M consensus. CEO Joe Walsh said the company delivered “solid” results with 34% SaaS revenue growth and a 16.0% adjusted EBITDA margin, while highlighting the transition toward a software-focused model and a shift to an AI-enabled unified platform.
Thryv Holdings, Inc. provides digital marketing and cloud-based software solutions for small and medium-sized businesses.
1. Mission Produce, Inc. (NASDAQ:AVO)
On March 19, 2026, Freedom Capital initiated coverage of Mission Produce, Inc. (NASDAQ:AVO) with a Buy rating and a $15 price target. Freedom Capital said the company is a global sourcing, production, and distribution business focused on Hass avocados, noting that global consumption continues to grow amid demand for healthy and fresh foods.
On March 12, 2026, Mission Produce, Inc. reported Q1 adjusted EPS of 10c, above the 7c consensus estimate, with revenue of $278.6M compared to the $260.73M consensus. CEO Steve Barnard said the company is off to a “strong start,” highlighting 14% volume growth and margin expansion driven by normalized pricing and operational execution, while emphasizing focus on volume growth and per-unit margin.
Mission Produce, Inc. expects FY26 capital expenditures of $40M, and President John Pawlowski said the pending Calavo Growers acquisition could deliver “at least $25 million” in annual synergies, with the transaction expected to close in the fiscal third quarter.
Mission Produce, Inc. sources, produces, and distributes avocados and other fruits globally.
READ NEXT: 10 Must-Buy Real Estate Stocks to Invest In and 11 Best High Volume Penny Stocks to Buy Now.
